Real-World Data, Clinical Practice So Far

Real-life data on the efficacy of anti-calcitonin gene–related peptide (GCRP) monoclonal antibodies (mAbs) have significantly enriched the knowledge on these innovative treatments indicated for migraine prevention. As of August 2020, ten observational studies on the efficacy and safety of erenumab have been published and a preliminary study on galcanezumab is available. Conversely, there are no real-life data on the two other mAbs.